Compounds > 1-deoxynojirimycin
Page last updated: 2024-08-23

1-deoxynojirimycin and Gangliosidoses, GM2

1-deoxynojirimycin has been researched along with Gangliosidoses, GM2 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Ashrafi, MR; Bemanalizadeh, M; Dakkali, MS; Daneshfar, S; Heidari, M; Hosseinpour, S; Khodarahmi, M; Mansouri, V; Sharifianjazi, F; Tavasoli, AR1
Alméciga-Díaz, CJ; Benincore-Flórez, E; Echeverri-Peña, OY; Espejo-Mojica, AJ; Garzón Jaramillo, RG; Leal, AF; Solano-Galarza, D; Suarez, DA1
Jarnes Utz, JR; Kim, S; King, K; Redtree, ES; Schema, L; Whitley, CB; Ziegler, R1
Banwell, B; Clarke, JT; Dingemanse, J; Maegawa, GH; Morgan, CP; Tifft, CJ; van Giersbergen, PL; Yang, S1
Bryan, C; Crooks, A; Ding, W; Dingemanse, J; O'Donnell, P; Prociuk, M; Sikora, T; Stein, VM; Vanier, MT; Vite, CH; Walkley, SU1
Butters, TD; d'Azzo, A; Dwek, RA; Elliot-Smith, E; Jeyakumar, M; Perry, VH; Platt, FM; Smith, DA; Thomas, R; van der Spoel, AC1

Reviews

2 review(s) available for 1-deoxynojirimycin and Gangliosidoses, GM2

ArticleYear
Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: A systematic review.
    European journal of neurology, 2023, Volume: 30, Issue:9

    Topics: 1-Deoxynojirimycin; Adult; Gangliosidoses, GM2; Humans

2023
GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.
    International journal of molecular sciences, 2020, Aug-27, Volume: 21, Issue:17

    Topics: 1-Deoxynojirimycin; beta-N-Acetylhexosaminidases; Blood-Brain Barrier; Clinical Trials as Topic; Diet, Ketogenic; G(M2) Activator Protein; G(M2) Ganglioside; Gangliosidoses, GM2; Genetic Therapy; Humans; Mutation; Pyrimethamine; Stem Cell Transplantation

2020

Trials

2 trial(s) available for 1-deoxynojirimycin and Gangliosidoses, GM2

ArticleYear
Infantile gangliosidoses: Mapping a timeline of clinical changes.
    Molecular genetics and metabolism, 2017, Volume: 121, Issue:2

    Topics: 1-Deoxynojirimycin; Diet, Ketogenic; Disaccharidases; Female; Gangliosidoses; Gangliosidoses, GM2; Gangliosidosis, GM1; Glycoside Hydrolase Inhibitors; Humans; Infant; Male; Prospective Studies; Retrospective Studies

2017
Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
    Molecular genetics and metabolism, 2009, Volume: 97, Issue:4

    Topics: 1-Deoxynojirimycin; Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Gangliosidoses, GM2; Glucosyltransferases; Humans; Infant

2009

Other Studies

2 other study(ies) available for 1-deoxynojirimycin and Gangliosidoses, GM2

ArticleYear
Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C.
    Journal of neuropathology and experimental neurology, 2012, Volume: 71, Issue:5

    Topics: 1-Deoxynojirimycin; Animals; Antigens, CD; Area Under Curve; Brain; Case-Control Studies; Cat Diseases; Cats; Cell Survival; Cholesterol; Enzyme Inhibitors; Follow-Up Studies; Gangliosidoses, GM2; Microglia; Niemann-Pick Disease, Type C; Phagocytosis; Phenotype; Postmortem Changes; Purkinje Cells; Reactive Oxygen Species; Sphingomyelins; Sphingosine; Time Factors

2012
Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
    Brain : a journal of neurology, 2003, Volume: 126, Issue:Pt 4

    Topics: 1-Deoxynojirimycin; Animals; Antigens, CD; Apoptosis; Biomarkers; Blood-Brain Barrier; Cytokines; Enzyme Inhibitors; Gangliosidoses; Gangliosidoses, GM2; Gangliosidosis, GM1; Genes, MHC Class II; Immunohistochemistry; Inflammation; Mice; Sandhoff Disease; Tay-Sachs Disease

2003